{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:40:02Z","timestamp":1756309202106,"version":"3.44.0"},"reference-count":12,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,7,5]]},"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:p>Recognition of new cutaneous side effects of combination chemotherapy can help prevent unnecessary cessation or reduction of cancer therapy. Periorbital rash has not been found with docetaxel alone, but here, we report it as a result of combination chemotherapy. A series of three patients who received docetaxel in combination with other chemotherapies developed clinically near-identical, distinctive periorbital rashes. Rashes resolved by resolving underlying docetaxel-induced epiphora in conjunction with ophthalmological consultation, topical skin-directed care, and in some cases, chemotherapy dose reduction. It is important for dermatologists and oncologists to recognise the increased severity of cutaneous reactions when docetaxel is used in combination chemotherapy.<\/jats:p>","DOI":"10.1136\/bcr-2019-230023","type":"journal-article","created":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T05:25:19Z","timestamp":1563773119000},"page":"e230023","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Periorbital dermatitis in patients receiving docetaxel in combination chemotherapy"],"prefix":"10.1136","volume":"12","author":[{"given":"Mika Michelle","family":"Tabata","sequence":"first","affiliation":[{"name":"Dermatology, Stanford University School of Medicine, Stanford, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernice","family":"Kwong","sequence":"additional","affiliation":[{"name":"Dermatology, Stanford Medicine, Stanford, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,7,21]]},"reference":[{"key":"2025082708023073000_12.7.e230023.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.6574"},{"key":"2025082708023073000_12.7.e230023.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.7577"},{"key":"2025082708023073000_12.7.e230023.3","first-page":"108","article-title":"A new rapid desensitization protocol for chemotherapy agents","volume":"21","author":"Gastaminza","year":"2011","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2025082708023073000_12.7.e230023.4","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaip.2018.09.018","article-title":"Role of Skin Tests in the Diagnosis of Immediate Hypersensitivity Reactions to Taxanes: Results of a Multicenter Study","volume":"7","author":"Pagani","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025082708023073000_12.7.e230023.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"2025082708023073000_12.7.e230023.6","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/j.jaad.2016.07.036","article-title":"General management strategy for epidermal growth factor receptor inhibitor-associated papulopustular eruption","volume":"75","author":"Farahnik","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2025082708023073000_12.7.e230023.7","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.urolonc.2017.08.005","article-title":"PD-1 checkpoint inhibition: Toxicities and management","volume":"35","author":"Hahn","year":"2017","journal-title":"Urol Oncol"},{"key":"2025082708023073000_12.7.e230023.8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/137414","article-title":"Drug resistance and the role of combination chemotherapy in improving patient outcomes","volume":"2013","author":"Yardley","year":"2013","journal-title":"Int J Breast Cancer"},{"key":"2025082708023073000_12.7.e230023.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2014.03.003"},{"key":"2025082708023073000_12.7.e230023.10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi279"},{"key":"2025082708023073000_12.7.e230023.11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp319"},{"key":"2025082708023073000_12.7.e230023.12","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/1756-0500-7-322","article-title":"Epiphora in lung cancer patients receiving docetaxel: a case series","volume":"7","author":"Yamagishi","year":"2014","journal-title":"BMC Res Notes"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-230023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:02:38Z","timestamp":1756306958000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-230023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":12,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7,21]]},"published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1136\/bcr-2019-230023"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-230023","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}